- Home
- WT vs GLPG Comparison
WT vs GLPG Comparison
Compare WT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WT
- GLPG
- Stock Information
- Founded
- WT 1985
- GLPG 1999
- Country
- WT United States
- GLPG Belgium
- Employees
- WT N/A
- GLPG N/A
- Industry
- WT Investment Bankers/Brokers/Service
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- WT Finance
- GLPG Health Care
- Exchange
- WT Nasdaq
- GLPG Nasdaq
- Market Cap
- WT 1.9B
- GLPG 2.1B
- IPO Year
- WT N/A
- GLPG 2005
- Fundamental
- Price
- WT $13.54
- GLPG $32.00
- Analyst Decision
- WT Buy
- GLPG Sell
- Analyst Count
- WT 5
- GLPG 4
- Target Price
- WT $12.48
- GLPG $25.33
- AVG Volume (30 Days)
- WT 3.3M
- GLPG 407.4K
- Earning Date
- WT 07-31-2025
- GLPG 07-23-2025
- Dividend Yield
- WT 0.89%
- GLPG N/A
- EPS Growth
- WT N/A
- GLPG N/A
- EPS
- WT 0.40
- GLPG N/A
- Revenue
- WT $444,568,000.00
- GLPG $323,674,692.00
- Revenue This Year
- WT $11.62
- GLPG N/A
- Revenue Next Year
- WT $10.76
- GLPG N/A
- P/E Ratio
- WT $33.45
- GLPG N/A
- Revenue Growth
- WT 15.43
- GLPG 5.43
- 52 Week Low
- WT $7.47
- GLPG $22.36
- 52 Week High
- WT $13.79
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- WT 67.66
- GLPG 53.21
- Support Level
- WT $11.64
- GLPG $31.32
- Resistance Level
- WT $13.79
- GLPG $32.63
- Average True Range (ATR)
- WT 0.31
- GLPG 0.71
- MACD
- WT -0.03
- GLPG -0.25
- Stochastic Oscillator
- WT 93.95
- GLPG 29.13
About WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. It offers a broad range of ETFs and exchange-traded products (ETPs). The firm also engages in developing next-generation digital products and structures, including digital funds and tokenized assets, as well as its blockchain-native digital wallet, WisdomTree Prime. The Company conducts business under a single operating segment as an ETP sponsor and asset manager.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.